Monopar Therapeutics (MNPR) Change in Cash (2017 - 2025)

Monopar Therapeutics has reported Change in Cash for 9 years, with the latest figure at -$65.8 million in Q4 2025.

• Quarterly Change in Cash fell 265.45% year-over-year to -$65.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (down 58.45% YoY) and the FY2025 annual result came in at $16.0 million, down 58.45% from the prior year.
• Change in Cash retreated to -$65.8 million in Q4 2025 per MNPR's latest filing, from $88.2 million in the prior quarter.
• Over five years, Change in Cash peaked at $88.2 million in Q3 2025 and troughed at -$65.8 million in Q4 2025.
• A 5-year average of $2.3 million and a median of -$1.6 million in 2021 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2021 and 2025: Change in Cash slumped 2997.62% in 2021, then jumped 88410.54% in 2025.
• Over 5 years, Change in Cash stood at -$2.0 million in 2021, then plunged by 200.84% to -$6.1 million in 2022, then soared by 128.56% to $1.8 million in 2023, then soared by 2173.12% to $39.8 million in 2024, then plunged by 265.45% to -$65.8 million in 2025.
• According to Business Quant data, Change in Cash over the past three periods registered -$65.8 million, $88.2 million, and -$209473.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.